Johnson & Johnson’s bispecific antibody Rybrevant (amivantamab) won accelerated FDA approval for head and neck cancer patients whose disease has come back after prior chemotherapy and immunotherapy. The approval extends the drug’s labeled oncology use beyond its earlier indication in certain lung cancers and supports continued regulatory momentum for multi-target antibody formats in solid tumors. For clinicians and payers, the key change is label expansion tied to prior treatment history rather than a new first-line positioning. The accelerated pathway also keeps attention on confirmatory evidence and durability of benefit in the broader head-and-neck population.